The Complex Clinical Picture of Side Effects to Anticoagulation

Medical Clinics of North America

Volumn 94, Issue 4, 2010, Pages 821-834

  Trautmann, Axel ^a   Seitz, Cornelia S ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Adverse drug reaction; Coumarin; Heparin; Hypersensitivity; Skin necrosis; Thrombocytopenia

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; CERTOPARIN; COUMARIN; DABIGATRAN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARINOID; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTOSAN POLYSULFATE; PHENPROCOUMON; REVIPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

ADVERSE DRUG REACTION; ALLERGY TEST; ANAPHYLAXIS; BLOOD CLOTTING; COUMARIN INDUCED SKIN NECROSIS; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DRUG CROSS REACTIVITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; THROMBOEMBOLISM;

ANAPHYLAXIS; ANTICOAGULANTS; COUMARINS; DRUG ERUPTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; HYPERSENSITIVITY, DELAYED; POLYSACCHARIDES; THROMBIN; THROMBOCYTOPENIA; VITAMIN K;

EID: 77953592455     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.03.003     Document Type: Review

References (75)

1. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 188-203
2. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 (2002) 1381-1389
3. Bauer K.A. New anticoagulants. Curr Opin Hematol 15 (2008) 509-515
4. Al Dieri R., Wagenvoord R., van Dedem G.W., et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain. J Thromb Haemost 1 (2003) 907-914
5. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (2001) 64-94
6. Blann A.D., Landray M.J., and Lip G.Y. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 325 (2002) 762-765
7. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008) 381-453
8. Keam S.J., and Goa K.L. Fondaparinux sodium. Drugs 62 (2002) 1673-1685
9. Weitz J.I., and Crowther M. Direct thrombin inhibitors. Thromb Res 106 (2002) 275-284
10. Kam P.C., Kaur N., and Thong C.L. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 60 (2005) 565-574
11. Gerotziafas G.T., and Samama M.M. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 11 (2005) 3855-3876
12. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 204-233
13. Hyers T.M. Management of venous thromboembolism: past, present, and future. Arch Intern Med 163 (2003) 759-768
14. Lassen M.R., and Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag 4 (2008) 1373-1386
15. Klein G.F., Kofler H., Wolf H., et al. Eczema-like, erythematous, infiltrated plaques: a common side effect of subcutaneous heparin therapy. J Am Acad Dermatol 21 (1989) 703-707
16. Trautmann A., and Seitz C.S. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am 29 (2009) 469-480
17. Trautmann A., Hamm K., Bröcker E.B., et al. [Delayed hypersensitivity to heparins. Clinical signs, diagnosis, therapeutic alternatives]. Z Hautkr 72 (1997) 447-450 [in German]
18. Bircher A.J., Flückiger R., and Buchner S.A. Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Br J Dermatol 123 (1990) 507-514
19. Guillet G., Delaire P., Plantin P., et al. Eczema as a complication of heparin therapy. J Am Acad Dermatol 20 (1989) 1130-1132
20. Korstanje M.J., Bessems P.J., Hardy E., et al. Delayed-type hypersensitivity reaction to heparin. Contact Dermatitis 20 (1989) 383-384
21. Kim K.H., and Lynfield Y. Enoxaparin-induced generalized exanthema. Cutis 72 (2003) 57-60
22. Seitz C.S., Bröcker E.B., and Trautmann A. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatol Online J 14 (2008) 4
23. Patrizi A., DiLernia V., and Patrone P. Generalized reaction to subcutaneous heparin. Contact Dermatitis 20 (1989) 309-310
24. Greiner D., and Schöfer H. [Allergic drug exanthema to heparin. Cutaneous reactions to high molecular and fractionated heparin]. Hautarzt 45 (1994) 569-572 [in German]
25. Estrada Rodriguez J.L., Gozalo R.F., Ortiz U., et al. Generalized eczema induced by nadroparin. J Investig Allergol Clin Immunol 13 (2003) 69-70
26. Grassegger A., Fritsch P., and Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study. Dermatol Surg 27 (2001) 47-52
27. Mendez J., Sanchis M.E., de la Fuente R., et al. Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy 53 (1998) 999-1003
28. Gaigl Z., Pfeuffer P., Raith P., et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 128 (2005) 389-392
29. Kroon C., de Boer A., Kroon J.M., et al. Influence of skinfold thickness on heparin absorption. Lancet 337 (1991) 945-946
30. Bircher A.J., Harr T., Hohenstein L., et al. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 61 (2006) 1432-1440
31. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis 17 (2006) 605-613
32. Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26 (2008) 669-675
33. Hermann K., Frank G., and Ring J. Contamination of heparin by histamine: measurement and characterization by high-performance liquid chromatography and radioimmunoassay. Allergy 49 (1994) 569-572
34. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358 (2008) 2457-2467
35. Liew G., Campbell C., and Thursby P. Delayed-type hypersensitivity to subcutaneous heparin with tolerance of i.v. administration. ANZ J Surg 74 (2004) 1020-1021
36. Boehncke W.H., Weber L., and Gall H. Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids. Contact Dermatitis 35 (1996) 73-75
37. Jappe U., Reinhold D., and Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis 46 (2002) 29-32
38. Trautmann A., Bröcker E.B., and Klein C.E. Intravenous challenge with heparins in patients with delayed-type skin reactions after subcutaneous administration of the drug. Contact Dermatitis 39 (1998) 43-44
39. Gaigl Z., Klein C.E., Großmann R., et al. [Managing allergy to heparin]. Dtsch Arztebl 103 (2006) 2877-2881 [in German]
40. Lindhoff-Last E., Kreutzenbeck H.J., and Magnani H.N. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93 (2005) 63-69
41. Ludwig R.J., Beier C., Lindhoff-Last E., et al. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 49 (2003) 158-159
42. Ludwig R.J., Schindewolf M., Alban S., et al. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 94 (2005) 1265-1269
43. Utikal J., Peitsch W.K., Booken D., et al. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 94 (2005) 895-896
44. Hirsch K., Ludwig R.J., Lindhoff-Last E., et al. Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis 50 (2004) 383-384
45. Hohenstein E., Tsakiris D., and Bircher A.J. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 51 (2004) 149-151
46. Maetzke J., Hinrichs R., Staib G., et al. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy. Allergy 59 (2004) 237-238
47. Reininger C.B., Greinacher A., Graf J., et al. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 81 (1996) 641-649
48. Greinacher A., Michels I., Liebenhoff U., et al. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 84 (1993) 711-716
49. Greinacher A., and Warkentin T.E. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 118 (2006) 165-179
50. Eichler P., Raschke R., Lubenow N., et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 116 (2002) 887-891
51. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 311-337
52. Shelley W.B., and Sayen J.J. Heparin necrosis: an anticoagulant-induced cutaneous infarct. J Am Acad Dermatol 7 (1982) 674-677
53. Yates P., and Jones S. Heparin skin necrosis-an important indicator of potentially fatal heparin hypersensitivity. Clin Exp Dermatol 18 (1993) 138-141
54. Balestra B. [Skin necrosis: a paradoxical complication of anticoagulation]. Schweiz Med Wochenschr 125 (1995) 361-364 [in German]
55. Warkentin T.E., Roberts R.S., Hirsh J., et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 127 (2005) 1857-1861
56. Kelly R.A., Gelfand J.A., and Pincus S.H. Cutaneous necrosis caused by systemically administered heparin. JAMA 246 (1981) 1582-1583
57. Alving B.M. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101 (2003) 31-37
58. Hirsh J., Heddle N., and Kelton J.G. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164 (2004) 361-369
59. Lubenow N., Kempf R., Eichner A., et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or re-exposure to heparin. Chest 122 (2002) 37-42
60. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
61. Potzsch B., Klovekorn W.P., and Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343 (2000) 515
62. Selleng S., Lubenow N., Wollert H.G., et al. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful re-exposure to heparin. Ann Thorac Surg 71 (2001) 1041-1042
63. Harr T., Scherer K., Tsakiris D.A., et al. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy 61 (2006) 787-788
64. Bottio T., Pittarello G., Bonato R., et al. Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. J Thorac Cardiovasc Surg 126 (2003) 1194-1195
65. Bircher A.J., Czendlik C.H., Messmer S.L., et al. Acute urticaria caused by subcutaneous recombinant hirudin: evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 98 (1996) 994-996
66. Greinacher A., Lubenow N., and Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108 (2003) 2062-2065
67. Greinacher A., Eichler P., Albrecht D., et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 101 (2003) 2617-2619
68. Blossom D.B., Kallen A.J., Patel P.R., et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 359 (2008) 2674-2684
69. Chan Y.C., Valenti D., Mansfield A.O., et al. Warfarin induced skin necrosis. Br J Surg 87 (2000) 266-272
70. Roche-Nagle G., Robb W., Ireland A., et al. Extensive skin necrosis associated with warfarin sodium therapy. Eur J Vasc Endovasc Surg 25 (2003) 481-482
71. Nazarian R.M., Van Cott E.M., Zembowicz A., et al. Warfarin-induced skin necrosis. J Am Acad Dermatol 61 (2009) 325-332
72. Miura Y., Ardenghy M., Ramasastry S., et al. Coumadin necrosis of the skin: report of four patients. Ann Plast Surg 37 (1996) 332-337
73. Anderson D.R., Brill-Edwards P., and Walker I. Warfarin-induced skin necrosis in 2 patients with protein S deficiency: successful reinstatement of warfarin therapy. Haemostasis 22 (1992) 124-128
74. Denton M.D., Mauiyyedi S., and Bazari H. Heparin-induced skin necrosis in a patient with end-stage renal failure and functional protein S deficiency. Am J Nephrol 21 (2001) 289-293
75. Jillella A.P., and Lutcher C.L. Reinstituting warfarin in patients who develop warfarin skin necrosis. Am J Hematol 52 (1996) 117-119